Whilst minimal-rely MBL rarely progresses to CLL, substantial-count MBL progresses to CLL necessitating therapy in a level of 1% to two% each year. Substantial-count MBL is distinguished from Rai 0 CLL depending on whether or not the B-cell rely is previously mentioned or under 5 × 109/L. Whilst persons with each substantial-count MBL and CLL Rai